Home › Sickle Cell Disease › NCT04093986

Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation

Who can join

All ages · All sexes

Inclusion Criteria:

* Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and/or while breastfeeding.
* Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.

Exclusion Criteria:

* Unavailable medical records or lack of information about hydroxyurea exposure.

About the study

The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.

What is being tested

• Chart Review (other)
• Survey (other)

Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 200 · Started: Dec 22, 2019

Contact the study team

• Teresa Latham · Phone: 513-803-7922

Official record on ClinicalTrials.gov — NCT04093986

Locations in the U.S.

Conditions

• Sickle Cell Disease

From ClinicalTrials.gov, data retrieved Oct 3, 2026. Each study sets its own eligibility; the study team decides who can join.